Organisation paid for research Program year 2025 Source: CMS Open Payments

Lehigh Valley Hospital

Neither a doctor nor a teaching hospital

Research payments

$440,900

79 payments

Through program year 2025, Lehigh Valley Hospital is reported as receiving $440,900 in research payments, across 79 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $5,625 4
2024 Research $191,898 24
2023 Research $70,620 13
2022 Research $20,253 11
2021 Research $43,029 11
2020 Research $70,963 8
2019 Research $38,512 8

Breakdown

Who paid Research payments · program years 2019–2025
  1. CathWorks, Inc. $181,582 16 payments
  2. ViiV Healthcare Company $135,279 34 payments
  3. OraSure Technologies Inc. $52,219 3 payments
  4. GlaxoSmithKline, LLC. $25,791 11 payments
  5. Novartis Pharmaceuticals Corporation $19,529 4 payments
  6. Provepharm Inc. $13,900 1 payment
  7. Bolton Medical Inc $5,625 4 payments
  8. Amgen Inc. $4,719 2 payments
  9. E.R. Squibb & Sons, L.L.C. $2,209 3 payments
  10. Merck Sharp & Dohme Corporation $47 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. All-Rise $181,582 16 payments
  2. A Phase Iiib, Randomized, Multicenter, Parallel-Group, Non-Inferiority $115,293 22 payments
  3. Performance of the OraQuick HIV Antibody Tests with Material and Procedure Replacements $26,383 1 payment
  4. A Phase Iiib, Multi-Center, Non-Randomized, Parallel-Group, Open-Label $25,791 11 payments
  5. Sample Acquisition Protocol for Development of Tests to Detect Antigens or Antibodies to Coronavirus $24,836 1 payment
  6. Pvp-Ic1901 $13,900 1 payment
  7. A Phase II Multicenter Three Cohort Study of Oral Cmet Inhibitor Inc280 in Adult Patients With Egfr Wild Type WT Advanced Non Small Cell Lung Cancer Nsclc Who Have Received One Or Two Prior Lines of Systemic Therapy Foradvanced Metastatic Disease $11,023 2 payments
  8. A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, No $10,494 9 payments
  9. A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed By Extended Treatment With Open-Label Remibrutinib $8,506 2 payments
  10. Panther $5,625 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record